Cybeats Technologies Corp. (CSE: CYBT) (OTCQB: CYBCF) has expanded an existing cybersecurity engagement with a global medical-device manufacturer while securing the first commercial deployment of its RAVEN artificial-intelligence platform.
The company announced a 76% revenue expansion of the existing six-figure engagement. Cybeats said the renewal increased the relationship’s revenue, scope and contract duration, although it did not disclose the revised contract value or term.
The customer will continue using SBOM Studio, Cybeats’ software supply-chain security platform. The expanded engagement also includes RAVEN, marking the AI-powered product’s first commercial rollout with a customer.
A software bill of materials, or SBOM, provides an inventory of the components and dependencies contained within a software product. Companies can use that information to identify vulnerable components, maintain audit records and respond to newly disclosed security threats.
RAVEN operates as an AI intelligence layer within SBOM Studio. Cybeats said the platform applies AI-powered reasoning to tasks including vulnerability prioritization, reachability analysis, evidence generation and software-component classification.
“This expansion demonstrates the confidence our customers have in SBOM Studio and the results they are achieving,” CEO Justin Leger said.
The medical-device manufacturer requested anonymity because of cybersecurity and procurement confidentiality. The absence of the customer’s identity and complete contract terms limits outside assessment of the agreement’s size, duration and potential contribution to future revenue.
Cybeats also reported eight active proof-of-concept engagements across healthcare, industrial and critical-infrastructure markets. These trials could provide future commercial opportunities, but they have not yet been identified as signed customer contracts.
The contract expansion follows Cybeats’ second-quarter financial results. Revenue increased 9.5% to C$815,769, while the quarterly net loss narrowed 4% to C$764,074.
Cybeats ended the quarter with C$261,643 in cash, down from C$1.07 million at the end of the first quarter. The company subsequently completed an oversubscribed C$1.9 million private placement intended to support commercial expansion, research and development and working capital.
For the first half of 2026, Cybeats recorded revenue of C$1.58 million and a C$3.20 million net loss. The loss included a C$1.57 million noncash expense associated with option grants.
Upcoming Catalysts
Future updates could provide information about the implementation of RAVEN within the medical-device customer’s security program and whether the expanded engagement contributes to additional recurring revenue.
Investors may also monitor whether Cybeats converts any of its eight active proof-of-concept engagements into commercial contracts. Subsequent financial results will indicate whether revenue growth and the recent financing are sufficient to support operations while the company works toward profitability.
Sources
- Cybeats Expands Medical-Device Manufacturer Contract by 76%
- Cybeats Reports Second-Quarter 2026 Financial Results
- Cybeats Corporate Website
- SEDAR+ Company Filings
Editorial Disclosure
This article is based entirely on publicly available information, including company news releases and regulatory filings. Securities discussed include Cybeats Technologies Corp. (CSE: CYBT) (OTCQB: CYBCF). NextGenTechStocks.com has not received compensation from Cybeats Technologies, its management, investor relations representatives or any third party for this specific article. NextGenTechStocks.com may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of NextGenTechStocks.com holds a position in any security mentioned at the time of publication.
Sources used include Cybeats’ contract-expansion announcement dated Sept. 3, 2026; its second-quarter financial-results announcement dated Aug. 31; and publicly available company and regulatory information.
Cybeats described the transaction as a 76% revenue expansion of an existing six-figure engagement but did not disclose the customer’s identity, revised contract value or duration. Its eight proof-of-concept engagements are not identified as signed commercial contracts. For Q2 2026, Cybeats reported C$815,769 in revenue, a C$764,074 net loss and C$261,643 in quarter-end cash before completing a C$1.9 million financing.
Financial information is current as of June 30, 2026. Contract and operational information is current as of Sept. 3, 2026. Cybeats remains exposed to customer-concentration, cybersecurity, product-performance, financing, sales-execution and competitive risks.
Small-cap and emerging-technology securities are speculative investments carrying significant risk, including the potential total loss of capital. NextGenTechStocks.com provides coverage for informational and educational purposes only and is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers should conduct their own due diligence and consult a qualified financial advisor before making investment decisions. Read our full DISCLAIMER.
